Printed from Voxsanity (voxsanity.com.au) — NCT07284875 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
People with a Body Mass Index (BMI) of 30 or higher, OR a BMI of 27 or higher combined with a prior diagnosis of at least one of the following: high blood pressure, abnormal cholesterol or fat levels in the blood, obstructive sleep apnea (where breathing repeatedly stops during sleep), or heart/blood vessel disease.
People who have tried at least once in the past 6 months to lose weight through diet and exercise without success (based on self-report).
Who may not be able to join:
People who have been diagnosed with diabetes, or have a history of diabetes.
People who started certain medications within the 3 months before screening that are known to cause significant weight gain, such as some antidepressants, antipsychotics, or mood stabilisers.
People whose weight has changed by more than 5% in the 3 months before screening (based on self-report).
People with a personal or family history of a condition called Multiple Endocrine Neoplasia Type 2, or a type of thyroid cancer called medullary thyroid cancer.
People with uncontrolled high blood pressure or unstable heart or blood vessel disease.
People with a history of inflammation of the pancreas (pancreatitis), whether long-term or short-term.
People with a known significant problem with how their stomach empties food, or who regularly take medications that affect how the digestive system moves food through the body.
People with a history of a suicide attempt.
People with a significant active or unstable diagnosis of Major Depressive Disorder or another severe psychiatric condition.
People who have been treated with certain weight- or blood sugar-related medications — including semaglutide, tirzepatide, or similar drug types — within the 3 months before screening.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Kailera Clinical Site, Charlestown, New South Wales
Kailera Clinical Site, Sydney, New South Wales
Kailera Clinical Site, Sydney, New South Wales
Kailera Clinical Site, Sydney, New South Wales
Kailera Clinical Site, Wollongong, New South Wales
Kailera Clinical Site, Sippy Downs, Queensland
Kailera Clinical Site, Norwood, South Australia
Kailera Clinical Site, Heidelberg Heights, Victoria
Kailera Clinical Site, Melbourne, Victoria
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT07284875
Sponsor: Kailera
Phase: Phase 3
Status: Recruiting
Condition: Obesity
Trial contact: 781-317-0291
More information: https://clinicaltrials.gov/study/NCT07284875
Eligibility summary (AI generated)
Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
People with a Body Mass Index (BMI) of 30 or higher, OR a BMI of 27 or higher combined with a prior diagnosis of at least one of the following: high blood pressure, abnormal cholesterol or fat levels in the blood, obstructive sleep apnea (where breathing repeatedly stops during sleep), or heart/blood vessel disease.
People who have tried at least once in the past 6 months to lose weight through diet and exercise without success (based on self-report).
Who may not be able to join:
People who have been diagnosed with diabetes, or have a history of diabetes.
People who started certain medications within the 3 months before screening that are known to cause significant weight gain, such as some antidepressants, antipsychotics, or mood stabilisers.
People whose weight has changed by more than 5% in the 3 months before screening (based on self-report).
People with a personal or family history of a condition called Multiple Endocrine Neoplasia Type 2, or a type of thyroid cancer called medullary thyroid cancer.
People with uncontrolled high blood pressure or unstable heart or blood vessel disease.
People with a history of inflammation of the pancreas (pancreatitis), whether long-term or short-term.
People with a known significant problem with how their stomach empties food, or who regularly take medications that affect how the digestive system moves food through the body.
People with a history of a suicide attempt.
People with a significant active or unstable diagnosis of Major Depressive Disorder or another severe psychiatric condition.
People who have been treated with certain weight- or blood sugar-related medications — including semaglutide, tirzepatide, or similar drug types — within the 3 months before screening.
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 16 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
Trial details
Status
Recruiting
Phase
Phase 3
Sponsor
Kailera
Registry
ClinicalTrials.gov
Start date
18 December 2025
Est. completion
28 February 2028
Where this trial is recruiting
🇦🇷 Argentina
🇦🇺 Australia
🇳🇿 New Zealand
🇬🇧 United Kingdom
🇺🇸 United States
10 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Dose 3 and 4 versus Placebo: Percent Change From Baseline in Body Weight at Week 76
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.